These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 22003937)

  • 1. Chemotherapy-induced peripheral neurotoxicity can be misdiagnosed by the National Cancer Institute Common Toxicity scale.
    Frigeni B; Piatti M; Lanzani F; Alberti P; Villa P; Zanna C; Ceracchi M; Ildebrando M; Cavaletti G
    J Peripher Nerv Syst; 2011 Sep; 16(3):228-36. PubMed ID: 22003937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multi-center assessment of the Total Neuropathy Score for chemotherapy-induced peripheral neurotoxicity.
    Cavaletti G; Jann S; Pace A; Plasmati R; Siciliano G; Briani C; Cocito D; Padua L; Ghiglione E; Manicone M; Giussani G;
    J Peripher Nerv Syst; 2006 Jun; 11(2):135-41. PubMed ID: 16787511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale.
    Cavaletti G; Frigeni B; Lanzani F; Piatti M; Rota S; Briani C; Zara G; Plasmati R; Pastorelli F; Caraceni A; Pace A; Manicone M; Lissoni A; Colombo N; Bianchi G; Zanna C;
    J Peripher Nerv Syst; 2007 Sep; 12(3):210-5. PubMed ID: 17868248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxaliplatin scale and National Cancer Institute-Common Toxicity Criteria in the assessment of chemotherapy-induced peripheral neuropathy.
    Kautio AL; Haanpää M; Kautiainen H; Leminen A; Kalso E; Saarto T
    Anticancer Res; 2011 Oct; 31(10):3493-6. PubMed ID: 21965767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools.
    Cavaletti G; Frigeni B; Lanzani F; Mattavelli L; Susani E; Alberti P; Cortinovis D; Bidoli P
    Eur J Cancer; 2010 Feb; 46(3):479-94. PubMed ID: 20045310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The total neuropathy score: a tool for measuring chemotherapy-induced peripheral neuropathy.
    Smith EM; Beck SL; Cohen J
    Oncol Nurs Forum; 2008 Jan; 35(1):96-102. PubMed ID: 18192158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS).
    Binda D; Vanhoutte EK; Cavaletti G; Cornblath DR; Postma TJ; Frigeni B; Alberti P; Bruna J; Velasco R; Argyriou AA; Kalofonos HP; Psimaras D; Ricard D; Pace A; Galiè E; Briani C; Dalla Torre C; Lalisang RI; Boogerd W; Brandsma D; Koeppen S; Hense J; Storey D; Kerrigan S; Schenone A; Fabbri S; Rossi E; Valsecchi MG; Faber CG; Merkies IS; ; Galimberti S; Lanzani F; Mattavelli L; Piatti ML; Bidoli P; Cazzaniga M; Cortinovis D; Lucchetta M; Campagnolo M; Bakkers M; Brouwer B; Boogerd W; Grant R; Reni L; Piras B; Pessino A; Padua L; Granata G; Leandri M; Ghignotti I; Plasmati R; Pastorelli F; Heimans JJ; Eurelings M; Meijer RJ; Grisold W; Lindeck Pozza E; Mazzeo A; Toscano A; Russo M; Tomasello C; Altavilla G; Penas Prado M; Dominguez Gonzalez C; Dorsey SG
    Eur J Cancer; 2013 Sep; 49(13):2910-8. PubMed ID: 23668917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy-induced polyneuropathy: major agents and assessment by questionnaires.
    Zedan AH; Vilholm OJ
    Basic Clin Pharmacol Toxicol; 2014 Aug; 115(2):193-200. PubMed ID: 24796774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective assessment of chemotherapy-induced peripheral neuropathy due to weekly paclitaxel in patients with advanced or metastatic breast cancer (CSP-HOR 02 study).
    Kuroi K; Shimozuma K; Ohashi Y; Hisamatsu K; Masuda N; Takeuchi A; Aranishi T; Morita S; Ohsumi S; Hausheer FH
    Support Care Cancer; 2009 Aug; 17(8):1071-80. PubMed ID: 19089463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statistical identification of predictors for peripheral neuropathy associated with administration of bortezomib, taxanes, oxaliplatin or vincristine using ordered logistic regression analysis.
    Kanbayashi Y; Hosokawa T; Okamoto K; Konishi H; Otsuji E; Yoshikawa T; Takagi T; Taniwaki M
    Anticancer Drugs; 2010 Oct; 21(9):877-81. PubMed ID: 20679888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A questionnaire survey of physicians' perspectives regarding the assessment of chemotherapy-induced peripheral neuropathy in patients with breast cancer.
    Kuroi K; Shimozuma K; Ohashi Y; Takeuchi A; Aranishi T; Morita S; Ohsumi S; Watanabe T; Bain S; Hausheer FH
    Jpn J Clin Oncol; 2008 Nov; 38(11):748-54. PubMed ID: 18845520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Electroclinical biomarkers of early peripheral neurotoxicity from oxaliplatin.
    McHugh JC; Tryfonopoulos D; Fennelly D; Crown J; Connolly S
    Eur J Cancer Care (Engl); 2012 Nov; 21(6):782-9. PubMed ID: 22594346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective surveillance model for physical rehabilitation of women with breast cancer: chemotherapy-induced peripheral neuropathy.
    Stubblefield MD; McNeely ML; Alfano CM; Mayer DK
    Cancer; 2012 Apr; 118(8 Suppl):2250-60. PubMed ID: 22488699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy-induced peripheral neuropathy-patient-reported outcomes compared with NCI-CTCAE grade.
    Tan AC; McCrary JM; Park SB; Trinh T; Goldstein D
    Support Care Cancer; 2019 Dec; 27(12):4771-4777. PubMed ID: 30972648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective Evaluation of Health Care Provider and Patient Assessments in Chemotherapy-Induced Peripheral Neurotoxicity.
    Alberti P; Bernasconi DP; Cornblath DR; Merkies ISJ; Park SB; Velasco R; Bruna J; Psimaras D; Koeppen S; Pace A; Dorsey SG; Argyriou AA; Kalofonos HP; Briani C; Schenone A; Faber CG; Mazzeo A; Grisold W; Valsecchi M; Cavaletti G;
    Neurology; 2021 Aug; 97(7):e660-e672. PubMed ID: 34078718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Chemotherapy-induced peripheral neuropathy].
    Noguchi E; Maeda Y
    Gan To Kagaku Ryoho; 2011 Nov; 38(11):1773-6. PubMed ID: 22083183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy induced peripheral neuropathy: the modified total neuropathy score in clinical practice.
    Vasquez S; Guidon M; McHugh E; Lennon O; Grogan L; Breathnach OS
    Ir J Med Sci; 2014 Mar; 183(1):53-8. PubMed ID: 23832573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale.
    Cavaletti G; Bogliun G; Marzorati L; Zincone A; Piatti M; Colombo N; Parma G; Lissoni A; Fei F; Cundari S; Zanna C
    Neurology; 2003 Nov; 61(9):1297-300. PubMed ID: 14610145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02.
    Shimozuma K; Ohashi Y; Takeuchi A; Aranishi T; Morita S; Kuroi K; Ohsumi S; Makino H; Mukai H; Katsumata N; Sunada Y; Watanabe T; Hausheer FH
    Support Care Cancer; 2009 Dec; 17(12):1483-91. PubMed ID: 19330359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy.
    Molassiotis A; Cheng HL; Leung KT; Li YC; Wong KH; Au JSK; Sundar R; Chan A; Ng TR; Suen LKP; Chan CW; Yorke J; Lopez V
    Brain Behav; 2019 Jun; 9(6):e01312. PubMed ID: 31063261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.